Orgenesis Enters into Collaboration Agreement with MIDA to Deploy OMPULs for Point-of-Care Research and Development of Promising Cell and Gene Therapies
March 18, 2021 07:00 ET
|
Orgenesis Inc.
GERMANTOWN, Md., March 18, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Enters Second Phase of Collaboration with Hospital Infantil Universitario Niño Jesús in Madrid with Exclusive License to Commercialize Celyvir Solid Tumor Therapy
March 11, 2021 07:00 ET
|
Orgenesis Inc.
GERMANTOWN, Md., March 11, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Provides Fiscal 2020 Year-End Results and Corporate Update; Expands POCare Therapeutic Pipeline, POCare Technologies, and POCare Network
March 09, 2021 07:00 ET
|
Orgenesis Inc.
Revenue increases 96% to $7.7 million for 2020 Projects to more than double in revenue for 2021 based on current contracts already in hand Orgenesis to host conference call today at 8:30AM ET ...
Orgenesis Mobile Processing Units and Labs (OMPULs) to be Used for Point-of-Care Production and Commercialization of Cell and Gene Therapies in Collaboration with Dong-a University Hospital and Cure Therapeutics in South Korea
March 08, 2021 07:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Schedules Fiscal 2020 Year-End Business Update Conference Call
March 04, 2021 11:15 ET
|
Orgenesis Inc.
GERMANTOWN, Md., March 04, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis to Present Today at the Winter Wonderland Conference-Best Ideas from the Buy-Side
February 16, 2021 07:00 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Third Quarter 2020 Revenue Increases 40% Reflecting Continued Progress of POCare Platform
November 05, 2020 08:30 ET
|
Orgenesis Inc.
Reports rapid advancement of therapeutic pipeline Announces new semi-automated cell and gene therapy processing units Reports cash and cash equivalents of $88.8 million as of September 30, 2020 ...
Orgenesis Announces Virtual 2020 Annual Meeting of Stockholders
November 03, 2020 15:15 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Completes Acquisition of Koligo Therapeutics and Announces Additional Acquisition of Icellator® Technology from Tissue Genesis in Related Transaction
October 19, 2020 06:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Announces Agreement to Acquire Koligo Therapeutics, a Leader in Personalized Cell Therapies
September 29, 2020 06:30 ET
|
Orgenesis Inc.
Acquisition to support accelerated commercialization of Koligo’s KYSLECEL®, a personalized islet cell therapy available in the U.S. for chronic and recurrent acute pancreatitis Goal to rapidly...